ORGANIZATION
Japan Pharma Group Calls for Careful Approach on PMP Deduction for Comparator Drugs
The government should hold careful discussions on a plan to deduct the price maintenance premium (PMP) from PMP-granted comparator drugs if their prices are referred to in the pricing of newly approved drugs that would not qualify for the PMP…
To read the full story
Related Article
ORGANIZATION
- JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
- Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
- FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
February 3, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





